KFO 228: Immunopathogenesis and Therapy of Glomerulonephritis

KFO 228：肾小球肾炎的免疫发病机制和治疗

• 批准号: 101885864
• 金额: --
• 依托单位: III. Medizinische Klinik und Poliklinik (Nephrologie, Rheumatologie - Nierentransplantation - Sektion Endokrinologie/Diabetologie)
• 依托单位国家: 德国
• 项目类别: Clinical Research Units
• 财政年份: 2009
• 资助国家: 德国
• 起止时间: 2008-12-31 至 2015-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/101885864?language=en
• 关键词: KFO; 228; Immunopathogenesis; Therapy; Glomerulonephritis

Glomerulonephritis as a disease category is one of the leading causes of end-stage renal disease in the Western world and is associated with increased morbidity and mortality. The most aggressive form of glomerulonephritis with the worst clinical outcome is rapidly progressive glomerulonephritis (RPGN). It represents a heterogeneous collection of disease entities. However, fundamental to each form of RPGN is the immune-mediated renal damage that consists of a specific immune reaction followed by an effector phase of inflammation. This pathophysiological concept is the current rationale for unspecific immunosuppressive therapy with corticosteroids and cytotoxic agents. The missing specificity of these therapeutic regimes, however, and the frequently disabling side effects are the main reasons for the urgent need to develop new and more specific individual therapeutic strategies. This Clinical Research Unit will bring together scientists with strong expertise in human and experimental glomerulonephritis, in cellular immunology and in renal pathology. Using state-of-the-art techniques and (transgenic) animal models, combined with prospective studies in a large cohort of patients with RPGN, this Clinical Research Unit seeks to better understand the immunopathogenesis of proliferative and crescentic glomerulonephritis. The contribution of cell-mediated immune responses in the development and progression of renal disease will be the main focus. These experimental approaches will identify, characterise and validate new diagnostic, prognostic and therapeutic targets for a more specific and less toxic treatment of human glomerulonephritis.

肾小球肾炎作为一种疾病，是西方国家终末期肾病的主要原因之一，并与发病率和死亡率的增加有关。最具侵袭性且临床转归最差的肾小球肾炎是快速进展性肾炎(RPGN)。它代表了疾病实体的异质集合。然而，每种形式的RPGN的基础都是免疫介导的肾脏损伤，包括特定的免疫反应和随后的炎症效应期。这一病理生理学概念是目前使用皮质类固醇和细胞毒剂进行非特异性免疫抑制治疗的基本原理。然而，这些治疗方案缺乏特异性，以及经常导致无效的副作用，是迫切需要开发新的和更具体的个体化治疗策略的主要原因。这个临床研究单位将汇集在人类和实验性肾小球肾炎、细胞免疫学和肾脏病理学方面具有丰富专业知识的科学家。使用最先进的技术和(转基因)动物模型，结合对大量RPGN患者的前瞻性研究，该临床研究单位试图更好地了解增生性和新月体肾炎的免疫发病机制。细胞免疫反应在肾脏疾病发生发展过程中的作用将是研究的主要焦点。这些实验方法将识别、表征和验证新的诊断、预后和治疗目标，以实现更特异、毒性更低的人类肾炎治疗。